Statement: Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.
Primary_evidence: Inclusion Criteria:   women >=18 years of age;   >=1 target lesion;   locally advanced or metastatic breast cancer;   demonstrated resistance to anthracycline;   >=2 regimens of chemotherapy for advanced/metastatic disease. Exclusion Criteria:   previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines;   previous treatment with paclitaxel or docetaxel for advanced/metastatic disease.